Department of Nephrology, Hospital 12 de Octubre, Avenida de Córdoba s/n, Madrid, Spain.
J Am Soc Nephrol. 2012 Oct;23(10):1753-60. doi: 10.1681/ASN.2012010063. Epub 2012 Sep 6.
The long-term outcome of patients with IgA nephropathy who present with normal renal function, microscopic hematuria, and minimal or no proteinuria is not well described. Here, we studied 141 Caucasian patients with biopsy-proven IgA nephropathy who had minor abnormalities at presentation and a median follow-up of 108 months. None of the patients received corticosteroids or immunosuppressants. We reviewed renal biopsies using the Oxford classification criteria. In this sample, 46 (32%) patients had mesangial proliferation, whereas endocapillary proliferation, focal glomerulosclerosis, and tubulointerstitial abnormalities were uncommon. Serum creatinine increases >50% and >100% were observed in five (3.5%) patients and one (0.7%) patient, respectively; no patients developed ESRD. After 10, 15, and 20 years, 96.7%, 91.9%, and 91.9% of patients maintained serum creatinine values less than a 50% increase, respectively. Using Cox proportional hazards regression, the presence of segmental glomerulosclerosis was the only factor that significantly associated with a >50% increase in serum creatinine. Clinical remission occurred in 53 (37.5%) patients after a median of 48 months. Proteinuria>0.5 and >1.0 g/24 h developed in 21 (14.9%) and 6 (4.2%) patients, respectively. Median proteinuria at the end of follow-up was 0.1 g/24 h, with 41 (29.1%) patients having no proteinuria. At presentation, 23 (16.3%) patients were hypertensive compared with 30 (21.3%) patients at the end of follow-up; 59 (41.8%) patients were treated with renin-angiotensin blockers because of hypertension or increasing proteinuria. In summary, the long-term prognosis for Caucasian patients with IgA nephropathy who present with minor urinary abnormalities and normal renal function is excellent.
患有 IgA 肾病的患者,其临床表现为肾功能正常、镜下血尿、微量或无蛋白尿,其长期预后尚不清楚。在这里,我们研究了 141 例经活检证实的 IgA 肾病患者,这些患者在发病时存在轻微异常,中位随访时间为 108 个月。这些患者均未接受皮质激素或免疫抑制剂治疗。我们使用牛津分类标准对肾活检标本进行了回顾性分析。在本样本中,46(32%)例患者存在系膜增生,而内皮下增生、局灶性肾小球硬化和肾小管间质病变则不常见。5 例(3.5%)患者的血清肌酐升高超过 50%,1 例(0.7%)患者的血清肌酐升高超过 100%;无患者进展至终末期肾病。10、15 和 20 年后,分别有 96.7%、91.9%和 91.9%的患者的血清肌酐值增加小于 50%。使用 Cox 比例风险回归分析,节段性肾小球硬化是唯一与血清肌酐增加超过 50%显著相关的因素。53 例(37.5%)患者在中位时间为 48 个月时达到临床缓解。21 例(14.9%)和 6 例(4.2%)患者的蛋白尿分别超过 0.5 g/24 h 和 1.0 g/24 h。随访结束时的平均蛋白尿为 0.1 g/24 h,41 例(29.1%)患者无蛋白尿。在发病时,23 例(16.3%)患者为高血压,而在随访结束时,30 例(21.3%)患者为高血压;由于高血压或蛋白尿增加,59 例(41.8%)患者接受了肾素-血管紧张素阻滞剂治疗。总之,临床表现为轻微尿路异常和肾功能正常的白人 IgA 肾病患者的长期预后良好。